AP NEWS TEST SITE
Listen
ADVERTISEMENT
Click to copy
Press release content from News Direct Corporation. The AP news staff was not involved in its creation.
Click to copy
Related topics

Algernon Pharmaceuticals forms Algernon NeuroScience subsidiary to advance DMT stroke program

PRESS RELEASE: Paid content from News Direct Corporation
Press release content from News Direct Corporation. The AP news staff was not involved in its creation.
January 4, 2023 GMT
None
None

--News Direct--

Algernon Pharmaceuticals CEO Christopher Moreau joined Proactive to share news that the company has decided to move its psychedelic DMT stroke program into a private company called Algernon NeuroScience. Moreau said AGN Neuro will stay private until it has advanced through to the completion of a Phase 2a stroke study planned for Q4, 2023. Following that, the company will consider a potential direct IPO listing on the NASDAQ.

Contact Details

Proactive Canada

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

View original content to download multimedia: https://newsdirect.com/news/algernon-pharmaceuticals-forms-algernon-neuroscience-subsidiary-to-advance-dmt-stroke-program-936820961

All contents © copyright 2023 The Associated Press. All rights reserved.